, /CNW/ – JDRF and Sanofi Canada have announced a partnership aimed at raising awareness of the chronic autoimmune disease type 1 diabetes (T1D) and the role screening can play in the early detection of the disease.
Nationally, the number of people diagnosed with T1D is increasing by an estimated 4.4% annually.this place Among the countries with the highest incidence of new T1D cases each year. Although many believe that T1D is only diagnosed in childhood and adolescence, it is common to be diagnosed in adulthood, accounting for more than 50% of all T1D cases. Traditionally, the diagnosis of T1D is made after the onset of clinical symptoms, such as excessive thirst, frequent urination, and weight loss, but underlying autoimmune damage to pancreatic beta cells may occur before these signs become apparent. It starts long before it becomes.
The progression of T1D unfolds through three recognizable stages. The first “silent” stage is characterized by the presence of autoantibodies and the absence of overt symptoms. Increasing awareness of the steps leading to the onset of clinical disease may reduce the risk of diabetic ketoacidosis (DKA), a life-threatening condition that often accompanies a diagnosis of T1D. Early detection could keep people out of the hospital and reduce a significant financial burden on the health care system.
,
JDRF Canada President and CEO
Through this partnership, JDRF Canada and Sanofi Canada will work to increase awareness of T1D and increase the potential for screening to benefit individuals and families at risk for the disease in the future. T1D screening is a key pillar of JDRF’s international strategy because it has the power to detect who is at risk and allows us to provide education and support to improve outcomes. This new partnership will focus on disseminating resources and support to Canadians at risk of developing T1D and their health care providers to promote a culture of proactive health care.
,
General Manager, General Pharmaceuticals, Sanofi Canada
At Sanofi, we believe diabetes education is an important tool for individuals living with diabetes and the healthcare professionals who care for them. At the core of our partnership with JDRF is a shared commitment to shedding light on the processes that lead to the development of T1D. By identifying the stages that precede clinical symptoms, we aim to equip individuals with the knowledge they need to make informed decisions about their health. Early detection allows individuals to face their eventual diagnosis with education and support to proactively manage their condition.
About JDRF
JDRF is the world’s leading organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to treat, prevent, and cure T1D and its complications. We are based on a grassroots model where people connect in local communities, collaborate locally for efficiency and broader fundraising impact, and come together on a national stage to share resources, passion and energy. It is a structured organization. JDRF partners across the T1D development pipeline, including academic institutions, government, and industry, to fund research and advocate for the delivery of innovative treatments to people living with T1D. Our staff and volunteers are and five international affiliates dedicated to advocacy, community engagement, and the vision of a world without T1D. For more information, visit jdrf.ca.
aSanofi match
Sanofi is an innovative global healthcare company with a single purpose: Pursuing scientific miracles to improve people’s lives. Spanning nearly 100 countries, our teams are committed to turning the impossible into the possible and transforming the practice of medicine. We bring potentially life-changing treatment options and life-saving vaccine protection to millions of people around the world, keeping sustainability and social responsibility at the heart of our goals. .
In Canada, Sanofi employs more than 2,000 people, invests 20% of its revenue in biopharmaceutical research each year, and represents CAD. Over the past decade, we have contributed to research and development that has created jobs, businesses and opportunities across the country.From a cutting-edge campus we research, develop, manufacture, commercialize and sell Sanofi products to people in this country and around the world.
In 2024, we will celebrate our 110th anniversary. What started as a small laboratory in May 1914 has grown into Canada’s largest biomanufacturing facility. Today, we remain committed to discovering, developing and bringing innovative medicine and vaccine solutions to those who need them.
SOURCE Sanofi-Aventis Canada Inc.
View original content and download multimedia. http://www.newswire.ca/en/releases/archive/April2024/20/c7499.html